Document Type

Patent

Publication Date

10-29-1991

Abstract

For treatment of acne the glucuronide of retinoic acid (retinoyl β-glucuronide) is orally administered to women of child-bearing age who are capable of conception. This therapy is safer than the oral administration of retinoic acid because retinoic acid glucuronide is essentially non-teratogenic at dose levels effective for the acne treatment. The retinoic acid glucuronide can be in all-trans or 13-cis form.

Patent Number

US 5,061,723

ISURF Reference Number

01229

Assignee

Iowa State University Research Foundation, Inc.,

Application Number

US 07/355,779

Date Filed

5-22-1989

Language

en

File Format

application/pdf

Share

COinS